https://orcid.org/0000-0003-4691-7183
References
- Ornello R, Degan D, Tiseo C, et al. Distribution and temporal trends from 1993 to 2015 of ischemic stroke subtypes: a systematic review and meta-analysis. Stroke. 2018;49(4):814–819. doi:10.1161/STROKEAHA.117.020031
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
- Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–2486. doi:10.1056/NEJMoa1313600
- Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370(26):2467–2477. doi:10.1056/NEJMoa1311376
- Simantirakis EN, Papakonstantinou PE, Chlouverakis GI, et al. Asymptomatic versus symptomatic episodes in patients with paroxysmal atrial fibrillation via long-term monitoring with implantable loop recorders. Int J Cardiol. 2017;231:125–130. doi:10.1016/j.ijcard.2016.12.025
- Simantirakis EN, Papakonstantinou PE, Kanoupakis E, et al. Recurrence rate of atrial fibrillation after the first clinical episode: a prospective evaluation using continuous cardiac rhythm monitoring. Clin Cardiol. 2018;41(5):594–600. doi:10.1002/clc.22904
- Page RL, Wilkinson WE, Clair WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 1994;89(1):224–227. doi:10.1161/01.CIR.89.1.224
- Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120–129. doi:10.1056/NEJMoa1105575
- Papakonstantinou PE, Simantirakis EN. Long-term rhythm monitoring with an implantable loop recorder in patients after the first clinical atrial fibrillation episode. Towards an individualized management. Minerva Cardioangiol. 2019;67(2):121–130. doi:10.23736/S0026-4725.19.04883-7
- Svennberg E, Tjong F, Goette A, et al. How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace. 2022;24(6):979–1005. doi:10.1093/europace/euac038
- Papakonstantinou PE, Tsioufis K. Optimizing anticoagulation management in atrial fibrillation: beyond the guidelines. how and for whom? J Cardiovasc Pharmacol. 2023;81(6):397–399. doi:10.1097/FJC.0000000000001405
- Dilaveris PE, Antoniou CK, Caiani EG, et al. ESC working group on e-Cardiology position paper: accuracy and reliability of electrocardiogram monitoring in the detection of atrial fibrillation in cryptogenic stroke patients( ): in collaboration with the Council on Stroke, the European Heart Rhythm Association, and the Digital Health Committee. Eur Heart J Digit Health. 2022;3(3):341–358. doi:10.1093/ehjdh/ztac026
- Van Gelder IC, Healey JS, Crijns H, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017;38(17):1339–1344. doi:10.1093/eurheartj/ehx042
- Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094–2099. doi:10.1161/CIRCULATIONAHA.113.007825
- Svendsen JH, Diederichsen SZ, Højberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet. 2021;398(10310):1507–1516. doi:10.1016/S0140-6736(21)01698-6
- Kirchhof P, Toennis T, Goette A, et al. Anticoagulation with Edoxaban in patients with atrial high-rate episodes. N Engl J Med. 2023;389(13):1167–1179. doi:10.1056/NEJMoa2303062
- Healey JS, Lopes RD, Granger CB, et al. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med. 2024;390(2):107–117. doi:10.1056/NEJMoa2310234
- Diener HC, Sacco RL, Easton JD, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906–1917. doi:10.1056/NEJMoa1813959
- Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–2201. doi:10.1056/NEJMoa1802686
- Papakonstantinou PE, Kalogera V, Charitos D, et al. When anticoagulation management in atrial fibrillation becomes difficult: focus on chronic kidney disease, coagulation disorders, and cancer. Blood Rev. 2024;65:101171. doi:10.1016/j.blre.2024.101171